Immunotherapy has transformed oncology, yet kidney complications increasingly affect outcomes. This review summarizes nephrotoxicity from immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) therapies, and bispecific T-cell engagers (BiTEs). ICIs remain most used, with acute interstitial nephritis (AIN) as the hallmark lesion, while glomerular diseases and electrolyte abnormalities are less common. CAR-T therapy, though highly effective in hematologic cancers, carries risks of cytokine release syndrome, tumor lysis syndrome, and acute kidney injury (AKI). BiTEs, particularly teclistamab, show higher AKI rates than CAR-T, though mechanisms remain unclear. Early recognition, tailored management, and multidisciplinary collaboration are essential to ensure safe therapy and preserve kidney function.
HerrmannSMAbudayyehAGuptaS, et al. Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int2025; 107(1): 21–32.
TawbiHASchadendorfDLipsonEJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med2022; 386(1): 24–34.
4.
MiaoJSiseMEHerrmannSM.Immune checkpoint inhibitor related nephrotoxicity: advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. Front Nephrol2022; 2: 1017921.
5.
HerrmannSMPerazellaMA.Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep2020; 5(8): 1139–1148.
6.
CortazarFBMarroneKATroxellML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int2016; 90(3): 638–647.
7.
SeethapathyHHerrmannSMSiseME.Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management. Kidney Med2021; 3(6): 1074–1081.
8.
KitchluAJhaveriKDWadhwaniS, et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep2021; 6(1): 66–77.
9.
KanduriSRCheungpasitpornWThongprayoonC, et al. Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies. Kidney Int Rep2021; 6(5): 1416–1422.
10.
JhaveriKDRosnerMH.Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know. Clin J Am Soc Nephrol2018; 13(5): 796–798.
11.
FarooquiNSy-GoJPTMiaoJ, et al. Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy. Mayo Clin Proc2022; 97(7): 1294–1304.
12.
CharkvianiMBrocheroMJVMohanA, et al. Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR-T cells. Nephrol Dial Transplant2025; 40(8): 1512–1521.
13.
GillSMausMVPorterDL.Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev2016; 30(3): 157–167.
14.
HerrmannSM.Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI? PRO. Kidney3602022; 3(5): 799–802.
BoussiotisVA.Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med2016; 375(18): 1767–1778.
17.
LeachDRKrummelMFAllisonJP.Enhancement of antitumor immunity by CTLA-4 blockade. Science1996; 271(5256): 1734–1736.
18.
ManoharSKompotiatisPThongprayoonC, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant2019; 34(1): 108–117.
19.
MohanABarbirEBHernandezLH, et al. Synergistic effect of teclistamab with PD-1 inhibition: a case of acute interstitial nephritis with dual immunotherapy. Clin Kidney J2025; 18(2): sfae425.
20.
GuptaSStrohbehnIAWangQ, et al. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. Kidney Int2022; 102(4): 930–935.
21.
CortazarFBKibbelaarZAGlezermanIG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol2020; 31(2): 435–446.
22.
GuptaSShortSAPSiseME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J ImmunoTher Cancer2021; 9(10): e003467.
23.
IsikBAlexanderMPManoharS, et al. Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events. Kidney Int Rep2021; 6(4): 1022–1031.
24.
SeethapathyHZhaoSChuteDF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol2019; 14(12): 1692–1700.
25.
GuvenDCOzbekDASahinTK, et al. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. Anticancer Drugs2023; 34(6): 783–790.
26.
ManoharSThongprayoonCCheungpasitpornW, et al. Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients. Kidney Int Rep2020; 5(2): 149–158.
27.
MohanAKrisanapanPTangpanithandeeS, et al. Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes. Am J Nephrol2024; 55(4): 439–449.
28.
SeethapathyHZhaoSStrohbehnIA, et al. Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney Int Rep2020; 5(10): 1700–1705.
29.
MiaoJHerrmannSM.Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis. Clin Kidney J2023; 16(11): 1834–1844.
30.
SeethapathyHRusibamayilaNChuteDF, et al. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant2021; 36(12): 2241–2247.
31.
WanchooRSakhiyaVJhaveriKD.Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System. Kidney Int2021; 100(4): 945–947.
32.
SeethapathyHHerrmannSMRashidiA.Immune checkpoint inhibitor-associated AKI: debates in diagnosis, management, and rechallenge. Semin Nephrol2022; 42(6): 151346.
33.
AnsonDNortonJChaucerB, et al. Ipilimumab- and nivolumab-induced colitis causing severe hypokalemia and QTc prolongation. Case Rep Oncol Med2019; 2019: 7896749.
34.
HerrmannSMAlexanderMPRomeroMF, et al. Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-A report of 3 cases. Kidney Med2020; 2(5): 657–662.
35.
CassolCSatoskarALozanskiG, et al. Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep2019; 4(8): 1152–1160.
36.
SiseMEWangQSeethapathyH, et al. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. J Immunother Cancer2023; 11(1): e006222.
37.
MoledinaDGWilsonFPPoberJS, et al. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight2019; 4(10): e127456.
38.
FarooquiNZaidiMVaughanL, et al. Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors. Kidney Int Rep2023; 8(3): 628–641.
39.
MoledinaDGObeidWSmithRN, et al. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. J Clin Invest2023; 133(13): e168950.
40.
GuptaSMistryKAlikhanFM, et al. Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis. Kidney Int2025; 108(3): 491–496.
41.
HeybeliCNathanMAHerrmannSM.Renal injury in the setting of immune checkpoint inhibitor: report of a case of hypothyroidism and the role of positron emission tomography. J Onco-Nephrol2020; 4(3): 112–116.
42.
GuptaSGreen-LingrenOBhimaniyaS, et al. F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury. J Clin Invest2024; 134(18): e182275.
43.
AwiwiMOAbudayyehAAbdel-WahabN, et al. Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases. Eur Radiol2023; 33(3): 2227–2238.
44.
VerheijdenRJde GrootJSFabriekBO, et al. Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials. J Clin Oncol2024; 42(31): 3713–3724.
45.
GuptaSGarcia-CarroCProsekJM, et al. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. J Immunother Cancer2022; 10(9): e005646.
46.
LinJSMamloukOSelametU, et al. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology2021; 10(1): 1877415.
47.
BarbirEBMohanAKoiralaP, et al. Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis. Nephrol Dial Transplant2025; 40(3): 602–604.
48.
MokuPBakowBMuthiahA, et al. Steroid refractory immune checkpoint induced acute interstitial nephritis salvaged by mycophenolate mofetil. Brown J Hosp Med2023; 2(2): 74097.
49.
YoussefNAbudayyehA.Immune checkpoint inhibitor-related acute kidney injury: management and challenges. Am J Nephrol2026; 57(2): 168–179.
50.
RosenbergSARestifoNP.Adoptive cell transfer as personalized immunotherapy for human cancer. Science2015; 348(6230): 62–68.
51.
NeelapuSSLockeFLBartlettNL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med2017; 377(26): 2531–2544.
52.
MaudeSLLaetschTWBuechnerJ, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med2018; 378(5): 439–448.
53.
RajeNBerdejaJLinY, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med2019; 380(18): 1726–1737.
54.
BoardmanAPGutgartsVFlynnJ, et al. Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy. Haematologica2025; 110(3): 651–664.
55.
León-RománJIacoboniGBermejoS, et al. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies. Clin Kidney J2024; 17(3): sfae027.
56.
GuptaSSeethapathyHStrohbehnIA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis2020; 76(1): 63–71.
57.
FitzgeraldJCWeissSLMaudeSL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med2017; 45(2): e124–e131.
58.
MoreauPGarfallALvan de DonkN, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med2022; 387(6): 495–505.
59.
RiedhammerCBassermannFBesemerB, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia2024; 38(2): 365–371.
60.
MartinTGMateosMVNookaA, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer2023; 129(13): 2035–2046.
61.
WenXXuG.Nephrotoxicity in bispecific antibodies recipients: focus on T-cell-engaging bispecific antibodies. Onco Targets Ther2024; 17: 545–556.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
